Grant of Options

Summary by AI BETAClose X

CRISM Therapeutics Corporation announced on June 30, 2026, the grant of options under its EMI Share Option Plan to directors Andrew Webb, Chris McConville, and Gerry Beaney. Andrew Webb received options for 504,000 ordinary shares at an exercise price of 10p, Chris McConville for 408,798 shares at 10p, and Gerry Beaney for 99,999 shares at 10p. These options will vest over two years, with one-third vesting on grant, one-third on the first anniversary, and one-third on the second anniversary, becoming exercisable on the second anniversary and expiring in June 2036.

Disclaimer*

UK 100

Latest directors dealings